Phase 2 study of Carboplatin plus nab-Paclitaxel for patients with PS 2 advanced NSCLC(TORG1426)

Phase 2

• Conditions: on small cell lung cancer

• Registration Number: JPRN-UMIN000019458
• Lead Sponsor: PO Thoracic Oncology Research Group

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-10-22
• Study Completion: 2018-09-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with serious infection and/or serious complications(gastrointestinal bleeding, or cardiac disorder, etc) 2) Patients with interstitial pneumonia (by Chest X-P) 3) Patients with prior radiotherapy to primary and /or target region. 4) Patient who is with contraindications to paclitaxel or carboplatin. 5) History of hypersensitivity for albumin products 6) History of poorly controlled pleural effusion,pericardial effusion and ascites 7) Patients with severe renal dysfunction 8) Patients with symptomatic brain metastases 9) Patients with active double cancer less than 5 years disease free period 10) History of Bone-marrow transplantation 11) History of Peripheral blood stem cell transplantation(PBSCT) 12) Patients who declined contraception. 13) Patients with uncontrollable diabetes or hypertension 14) Patients with hepatic cirrhosis

Study & Design

• Study Type: Interventional
• Study Design: Not specified